| DC22715 |
RP-67580 |
A potent and selective tachykinin NK1 receptor antagonist with Ki of 2.9 nM. |
|
| DC23840 |
IN-1233 |
A potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 34 nM, prevents tissue hyperplasia in the rat urethra or common iliac artery.. |
|
| DC23839 |
IN-1233 phosphate |
A potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 34 nM, prevents tissue hyperplasia in the rat urethra or common iliac artery.. |
|
| DC22380 |
NNC 55-0396 2HCl
Featured
|
NNC 55-0396, Mibefradil derivative, is a highly selective T-type calcium channel blocker; displays IC50 values of 6.8 and > 100 μM for inhibition of Cav3.1 T-type channels and HVA currents respectively in INS-1 cells. IC50 value: 6.8 nMTarget: Cav3.1 T-type channelNNC 55-0396 can be an essential tool in preventing human ovarian cancer cell proliferation as a result of its ability to inhibit the function of T-type Ca2+ channels. It is believed that NNC 55-0396 may functions by dissolving in or passing through the plasma membrane of cells. |
|
| DC22534 |
PI4KIIIbeta-IN-10
Featured
|
A potent and selective type III phosphatidylinositol 4-kinase (PI4KIIIβ) inhibitor with IC50 of 3.6 nM. |
|
| DC23086 |
Vandetanib hydrochloride |
A potent and selective VEGFR2 (KDR) inhibitor with IC50 of 40 nM. |
|
| DC25087 |
Vandetanib trifluoroacetate |
A potent and selective VEGFR2 (KDR) inhibitor with IC50 of 40 nM. |
|
| DC11984 |
AMG 8379 |
A potent and selective voltage-gated sodium channel Nav1.7 antaognist with IC50 of 8.5 nM. |
|
| DC20627 |
ABT 089 dihydrochloride |
A potent and selective α4β2 nAChR agonist with Ki of 16 nM. |
|
| DC22885 |
TAN-67 dihydrobromide |
A potent and selective δ-opioid receptor agonist that has high affinity and selectivity for the δ1 subtype with Ki of 1.12 nM. |
|
| DC11670 |
MK-4409 |
A potent and selective, brain penetrant FAAH inhibitor with IC50 of 11 nM. |
|
| DC23520 |
VU 6001966 |
A potent and selective, CNS penetrant mGlu2 negative allosteric modulator with IC50 of 78 nM. |
|
| DC23521 |
VU 6010572 |
A potent and selective, CNS penetrant mGlu3 negative allosteric modulator with IC50 of 245 nM. |
|
| DC22979 |
PF-04822163 |
A potent and selective, CNS-penetrant PDE1 inhibitor with IC50 of 2.4 nM for PDE1B.. |
|
| DC22978 |
PF-04471141 hydrochloride |
A potent and selective, CNS-penetrant PDE1 inhibitor with IC50 of 35 nM for PDE1B.. |
|
| DC22802 |
MK2-IN-28 |
A potent and selective, non-ATP competitive, allosteric MAPKAPK2/3 (MK2/3) inhibitor with IC50 of 8 nM for MK2, hTNFα EC50 of 0.31 uM. |
|
| DC20888 |
Fadrozole |
A potent and selective, orally bioavailable aromatase inhibitor with IC50 of 1.7 nM, 180 times more potent than aminoglutethimide. |
|
| DC21004 |
EXEL-8232 |
A potent and selective, orally bioavailable JAK2 inhibitor with IC50 of 2 nM. |
|
| DC23843 |
BMS-935177 |
A potent and selective, orally bioavailable, reversible BTK inhibitor with IC50 of 2.8 nM. |
|
| DC22913 |
WEB-2086
Featured
|
A potent and specific antagonist of platelet activating factor (PAF) receptor that inhibits PAF-induced human platelet and neutrophil aggregation in vitro with IC50 of 0.17 and 0.36 uM, respectively. |
|
| DC23392 |
RX-37 |
A potent and specific BET bromodomain inhibitor with Ki of 3.2-24.7 nM for BD1 and BD2 domains of BRD2, BRD3, and BRD4. |
|
| DC22375 |
RS-102895
Featured
|
RS102895 is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1. |
|
| DC22432 |
CCX2553 |
A potent and specific CCR6 antagonist. |
|
| DC24199 |
OSU-T315 (ILK-IN-1)
Featured
|
OSU-T315 (ILK-IN-1) is a potent and specific integrin-linked kinase (ILK) inhibitor which inhibits PDK2 function in the AKT pathway activation |
|
| DC22444 |
Leptomycin B
Featured
|
A potent and specific nuclear export inhibitor that binds to and inhibits CRM1 (XPO1). |
|
| DC23495 |
DBIBB |
A potent and specific, nonlipid agonist of LPA2 receptor with EC50 of 100 nM, without activating or inhibiting LPA1/3/4/5 receptors. |
|
| DC22771 |
Proxalutamide
Featured
|
Proxalutamide (GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) for the potential treatment of COVID-19, prostate cancer, and breast cancer. |
|
| DC25033 |
EGA |
A potent anthrax lethal toxin entry inhibitor with IC50 of 1.7 uM, inhibits endosomal trafficking pathways exploited by multiple toxins and viruses. |
|
| DC21425 |
NSC639829 |
A potent anticancer agent that demonstrates potent antitumor activity in vitro against several cancer cell lines as well as in vivo against several tumor models, effectively inhibits in vitro tubulin polymerization. . |
|
| DC11901 |
Leflutrozole |
A potent aromatase inhibitor for the treatment of hypogonadism.. |
|
